Frankfurt
25.04.25
15:29 Uhr
2,860 Euro
-0,020
-0,69 %
-0,69 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.04. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 10.04. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| NANOBIOTIX SA ADR Aktie jetzt für 0€ handeln | |||||
| 04.04. | Guggenheim cuts Nanobiotix stock target to $8, maintains buy | 4 | Investing.com | ||
| 02.04. | Nanobiotix GAAP EPS of -€1.44 | 1 | Seeking Alpha | ||
| 02.04. | Nanobiotix S.A. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 02.04. | Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results | 98 | GlobeNewswire (Europe) | Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and... ► Artikel lesen | |
| 31.03. | Nanobiotix S.A.: NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 | 1 | GlobeNewswire (USA) | ||
| 27.03. | Nanobiotix reports promising NSCLC treatment study results | 1 | Investing.com | ||
| 27.03. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.03. | Nanobiotix S.A.: Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC | 278 | GlobeNewswire (Europe) | Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failedA preliminary review of... ► Artikel lesen | |
| 18.03. | Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden | 3 | Benzinga.com | ||
| 18.03. | Nanobiotix tweaks J&J licensing deal for phase 3 cancer drug to eke out cash | 13 | FierceBiotech | ||
| 17.03. | Nanobiotix S.A.: NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026 | 130 | GlobeNewswire (Europe) | PARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-stage clinical biotechnology company pioneering disruptive nanotherapeutic... ► Artikel lesen | |
| 13.03. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 2 | GlobeNewswire (USA) | ||
| 13.03. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 12.02. | Nanobiotix S.A.: Voting Rights and Shares Capital of the Company | 1 | GlobeNewswire (USA) | ||
| 12.02. | Nanobiotix S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 29.01. | Nanobiotix S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 21.01. | Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study | 1 | Zacks | ||
| 21.01. | Nanobiotix S.A. - 6-K, Report of foreign issuer | 5 | SEC Filings |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,187 | +2,52 % | Palatin Aktie: Gefährdete Stabilität! | Biotech-Firma Palatin kämpft gegen Börsenausschluss, während Orphan-Drug-Kandidat Hoffnung weckt. Kann die Pipeline die Finanzkrise abwenden? Die Uhr tickt für Palatin Technologies: Das Biotech-Unternehmen... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,680 | +5,51 % | COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer | 25+ years of experience in executive leadership roles and developing global strategic growth plans with repeatable models applicable across markets, categories and channels Current President and CEO... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 52,60 | +1,04 % | Merck & Co: Gewinnprognose gekappt - Halozyme klagt | Der US-amerikanische Pharma-Riese Merck & Co muss seine Ziele für das laufende Geschäftsjahr nach unten anpassen. Vor allem das schwächelnde Geschäft mit dem Impfstoff Gardasil in China belastet das... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 2,267 | -0,57 % | AbCellera Biologics Aktie: Die Falle schnappt zu? | AbCellera Biologics Inc. (ABCL) hat kürzlich Informationen zu seinen Forschungsinitiativen und finanziellen Ergebnissen veröffentlicht, die den laufenden Übergang zu einem Biotechnologieunternehmen... ► Artikel lesen | |
| GLOW LIFETECH | 0,037 | 0,00 % | Glow LifeTech Corp.: Glow Lifetech Triples Capacity via Automated Production Line as MOD Becomes #2 Oils SKU in Ontario | Toronto, Ontario--(Newsfile Corp. - March 25, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is accelerating its expansion with the acquisition of a... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 217,20 | -1,05 % | Should You be Optimistic on Bio-Rad Laboratories's (BIO) Outlook? | ||
| AVID BIOSERVICES | 12,100 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 05.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 05.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 05.02.2025ISIN NameCA75525M1095 RAZOR... ► Artikel lesen | |
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd.: BioLineRx Reports 2024 Financial Results and Provides Corporate Update | - Reports meaningful progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare diseases -
- Executed license... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 1,360 | +1,49 % | Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company | New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision
Upon closing of strategic transactions, cash expected... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 1,500 | -2,60 % | Minerva Neurosciences, Inc. - 10-K/A, Annual Report | ||
| APPLIED THERAPEUTICS | 0,370 | +7,51 % | Applied Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| GEOVAX LABS | 2,685 | -100,00 % | Nitches, inc: Nitches Inc. Updates Shareholders on Amazon Integration, GovX Integration, and 2025 Growth Strategy for InTheZone Labs | LAS VEGAS, NV / ACCESSWIRE / December 18, 2024 / Nitches Inc. (OTC PINK:NICH) is pleased to share key updates regarding the recent strides made with its InTheZone Labs brand, highlighting successful... ► Artikel lesen | |
| OVID THERAPEUTICS | 0,270 | +19,47 % | Ovid Therapeutics Aktie: Rückschritte statt Erfolge? | Biopharma-Unternehmen kämpft mit Kursverlusten trotz gefüllter Kassen und vielversprechender Entwicklungen bei Medikamentenkandidaten für neurologische Erkrankungen Ovid Therapeutics hat kürzlich Updates... ► Artikel lesen | |
| COCRYSTAL | 1,180 | -9,23 % | Cocrystal Pharma, Inc.: Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants | Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025Cocrystal Pharma's pan-viral... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 4,780 | -1,65 % | Precision BioSciences, Inc.: Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B | Approval in Hong Kong marks the first clinical trial application clearance of an in vivo gene editing approach for chronic hepatitis B in Hong Kong and the second CTA approval for PBGENE-HBV in 2024
... ► Artikel lesen |
NANOBIOTIX SA ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,020 (-0,69 %) liegt der Kurs bei 2,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOBIOTIX SA ADR finden Sie auf Wallstreet Online.
